Share This:
https://ntp.niehs.nih.gov/go/3272

TDMS Study 05099-99 Pathology Tables


                              INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
                                                      SALICYLAZOSULFAPYRIDINE


NTP Experiment-Test: 05099-99                                                                                     Report: PEIRPT05
Study Type: CHRONIC                                                                                               Date: 05/04/95
Route: GAVAGE                                                                                                     Time: 15:02:33


                                               05099/08 -VS- 05099/10 COMPARISON


       Facility:  SOUTHERN RESEARCH INSTITUTE

       Chemical CAS #:  599-79-1

       Lock Date:  04/19/94

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25017 Scheduled Sacrifice
                               25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include 001    0 MG/KG
                               Include 004    RTD     0 MG/KG




























a  Number of animals examined microscopically at site and number of animals with lesion

                                                             Page   1

NTP Experiment-Test: 05099-99  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 15:02:33  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 

  Animals Initially in Study                          60          110                                                               

  Scheduled Sacrifice                                              42                                                               
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 5            6                                                               
    Natural Death                                      3            4                                                               
    Dosing Accident                                    2                                                                            
  Survivors                                                                                                                         
    Terminal Sacrifice                                40                                                                            

  Animals Examined Microscopically                    50           52                                                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Small, Duodenum                          (47)         (51)                                                             
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                                                          
   Intestine Small, Jejunum                           (47)         (51)                                                             
      Adenocarcinoma                                                1 (2%)                                                          
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                                                          
   Intestine Small, Ileum                             (47)         (51)                                                             
   Liver                                              (50)         (52)                                                             
      Hemangioma                                       1 (2%)                                                                       
      Hemangiosarcoma                                  2 (4%)                                                                       
      Hepatocellular Carcinoma                        12 (24%)      6 (12%)                                                         
      Hepatocellular Carcinoma, Multiple               1 (2%)       1 (2%)                                                          
      Hepatocellular Adenoma                          12 (24%)     13 (25%)                                                         
      Hepatocellular Adenoma, Multiple                 1 (2%)                                                                       
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (2%)                                                          
   Mesentery                                          (4)          (6)                                                              
      Fat, Sarcoma                                                  1 (17%)                                                         
   Pancreas                                           (50)         (52)                                                             
      Carcinoma, Metastatic, Lung                      1 (2%)                                                                       
      Acinus, Adenoma                                  1 (2%)                                                                       
   Salivary Glands                                    (50)         (52)                                                             
   Stomach, Forestomach                               (50)         (52)                                                             
      Squamous Cell Papilloma                          3 (6%)       2 (4%)                                                          
   Stomach, Glandular                                 (50)         (52)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    

                                                             Page   2                                                               
NTP Experiment-Test: 05099-99  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 15:02:33  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (52)                                                             
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (52)                                                             
      Carcinoma, Metastatic, Lung                      1 (2%)                                                                       
      Capsule, Adenoma                                 1 (2%)                                                                       
   Adrenal Medulla                                    (50)         (52)                                                             
      Carcinoma, Metastatic, Lung                      1 (2%)                                                                       
   Islets, Pancreatic                                 (50)         (52)                                                             
      Adenoma                                          1 (2%)                                                                       
   Pituitary Gland                                    (44)         (48)                                                             
      Pars Distalis, Adenoma                           1 (2%)                                                                       
      Pars Intermedia, Carcinoma                       1 (2%)                                                                       
   Thyroid Gland                                      (50)         (52)                                                             
      Follicular Cell, Adenoma                         1 (2%)       1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (3)          (4)                                                              
      Mediastinal, Carcinoma, Metastatic,                                                                                           
          Harderian Gland                                           1 (25%)                                                         
   Lymph Node, Mandibular                             (50)         (51)                                                             
      Carcinoma, Metastatic, Kidney                                 1 (2%)                                                          
   Lymph Node, Mesenteric                             (50)         (52)                                                             
   Spleen                                             (50)         (52)                                                             
      Hemangiosarcoma                                  1 (2%)       1 (2%)                                                          
   Thymus                                             (45)         (51)                                                             
      Carcinoma, Metastatic, Harderian Gland                        1 (2%)                                                          
      Carcinoma, Metastatic, Lung                      1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    

                                                             Page   3                                                               
NTP Experiment-Test: 05099-99  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 15:02:33  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (52)                                                             
      Subcutaneous Tissue, Carcinoma, Metastatic,                                                                                   
           Harderian Gland                                          1 (2%)                                                          
      Subcutaneous Tissue, Hemangiosarcoma             1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (52)                                                             
      Rib, Carcinoma, Metastatic, Harderian Gland                   1 (2%)                                                          
   Skeletal Muscle                                                 (2)                                                              
      Carcinoma, Metastatic, Harderian Gland                        1 (50%)                                                         
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (50%)                                                         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (52)                                                             
      Alveolar/Bronchiolar Adenoma                     9 (18%)     10 (19%)                                                         
      Alveolar/Bronchiolar Adenoma, Multiple           2 (4%)       1 (2%)                                                          
      Alveolar/Bronchiolar Carcinoma                   3 (6%)       2 (4%)                                                          
      Hepatocellular Carcinoma, Metastatic, Liver      4 (8%)       1 (2%)                                                          
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (2%)                                                          
      Mediastinum, Carcinoma, Metastatic,                                                                                           
          Harderian Gland                                           1 (2%)                                                          
   Nose                                               (50)         (52)                                                             
      Glands, Carcinoma, Metastatic, Harderian                                                                                      
          Gland                                                     1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (3)          (3)                                                              
      Adenoma                                          2 (67%)      2 (67%)                                                         
      Carcinoma                                        1 (33%)      1 (33%)                                                         
____________________________________________________________________________________________________________________________________
                                                                                                                                    

                                                             Page   4                                                               
NTP Experiment-Test: 05099-99  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 15:02:33  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (52)                                                             
      Cortex, Carcinoma                                             1 (2%)                                                          
      Cortex, Carcinoma, Metastatic, Harderian                                                                                      
          Gland                                                     1 (2%)                                                          
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   

   Multiple Organs                                   *(50)        *(52)                                                             
      Lymphoma Malignant                               5 (10%)      6 (12%)                                                         
____________________________________________________________________________________________________________________________________

                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 

                                                             Page   5                                                               
NTP Experiment-Test: 05099-99  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 15:02:33  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            40          37                                                               
     Total Primary Neoplasms                           62          49                                                               
                                                                                                                                    
   Total Animals with Benign Neoplasms                 26          26                                                               
     Total Benign Neoplasms                            35          29                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms              25          18                                                               
     Total Malignant Neoplasms                         27          20                                                               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              5           4                                                               
     Total Metastatic Neoplasm                          8          16                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           1                                                               
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    

____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              

                                                             Page   6                                                               
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------